More Symprove IBS Research
Listed Under: Symprove News
More Symprove IBS Research Results
Symprove has been tested independently by University College London to establish if it arrived, survived and thrived in the gut. It was tested against other beneficial bacteria (probiotic) products on the market The full article is here: http://wageningenacademic.metapress.com/content/b6t42045019lh212/?p=f25061005c074a1cb28cc1e4e877b204&pi=0#.VK_TxCsV18F
For a probiotic to be effective in restoring the balance of bacteria in the gut, it has to do 3 things.
1: ARRIVE alive right from the start so it’s ready to get to work.
2: SURVIVE the strongly acidic and hostile environment of your stomach.
3: THRIVE in the intestines and targeted areas of your gut quickly and effectively.
Independent UCL Results
Below is a synopsis of the findings at UCL:
Stage 1: Did the amount of bacteria claimed in the product actually arrive?
This test was to establish if the 75% or more of the amount of bacteria claimed on the pack arrived. Of the 8 products tested, only the dairy based (yoghurts) and water-based (Symprove) products delivered at least 75% of the amount of bacteria claimed.
Stage 2: Did the bacteria survive through the stomach?
This test was conducted to establish if bacteria were able to survive stomach acid. It was carried out using Porcine Gastric Fluid – which is the best simulation of human gastric fluid. This test was to determine whether, in typical fed state, and after 120 minutes stomach transit time, there were still 1 million bacteria per ml.
UCL Findings: The research found that only two products actually survived through the stomach and that of these two, only Symprove remained stable.
Stage 3: Did the bacteria thrive in targeted areas of the gut?
This test was to establish if after 30 minutes exposure, the bacteria grew strongly within 10 hours to colonise in the gut.
UCL Findings: Only three products showed signs of strong growth within 10 hours. Others showed very slow, or even no growth.
Conclusion from all three tests: Symprove is the only product tested successfully to pass all 3 conducted tests.
The large number of probiotic products now available makes the decision about which product to choose difficult both for the consumer and for those providing dietary/nutritional advice. Data on the viability of the bacteria in these products, in the in-vivo situation, is therefore important. This study was designed to explore the comparative health and survival of probiotic species in various commercial products, using more realistic test systems that might allow further understanding of factors that must be controlled to give the greatest chance of delivery of live healthy probiotic bacteria to the lower gut.
A total of eight commercially available probiotic preparations were selected for enumeration tests and in-vitro gastric tolerance tests. Tolerance experiments were conducted in porcine gastric fluid (PGF) fed and fasted state (pH 3.4 ± 0.04), simulated gastric fluid (SGF, pH adjusted to 1.2 and 3.4) and fasted state simulated gastric fluid (FaSSGF, pH adjusted to 1.6 and 3.4). Isothermal microcalorimetry was also used to measure real-time growth of probiotics after exposure to simulated gastric fluid.
•Arrive - Results showed that not all probiotic products deliver ‘live’ bacteria. Freeze-dried products are not ‘alive’ and lose many of their bacteria as they attempt to recover to an active state. Only dairy-based or water-based (Symprove) probiotics delivered 100% or more than the claimed content.
•Survive - Results from the in-vitro tolerance tests overall suggest that the PGF provided a harsher environment than the simulated systems at similar pH.The initial acid shock, after only 5 minutes, was dramatic on almost all products, with some showing almost complete collapse. Only two products survived until typical stomach transit time (120 minutes), with one of these continuing to decline. Only one product seems stable, this was Symprove.
•Thrive - Results from tests in the fed state in PGF suggested that food greatly affects viability. Microcalorimetric data showed that for some products probiotic species were able to grow following exposure to gastric fluid, suggesting that viable bacteria reach the gut in-vivo. However, only three products showed signs of strong growth within 10 hours. Others showed very slow, or even no growth, meaning they would be passed from the intestines before they began growing. Symprove showed strong and fast growth.
•In the real world, a Probiotic has to meet all three challenges. Symprove is the ONLY product that achieved this.
King’s College Results
King's College London clinical trial
An Independent study was carried out at King’s College London by Dr Guy Sisson and Professor Ingvar Bjarnason to establish the effectiveness of Symprove in IBS.This was a randomised, double-blind, placebo-controlled study and one of the first to address the efficacy of a probiotic using standards such as are used with a drug trial.
The study was carried out on 186 IBS sufferers, mostly moderate to severe, who received a daily dose of Symprove or an identical placebo liquid for 3 months.
Symprove’s effects on:
The significant change in pain score is important as pain is regarded as the key measure for patient health.
Patients reported an improvement in their satisfaction with their bowel habit – both with constipation and diarrhoea – an unusual result in IBS treatments.
Results show that this multi-strain probiotic is safe, well-tolerated and efficacious in improving overall symptom severity in patients with IBS.
At study end, patients using Symprove had a statistically significantly greater improvement in IBS-SSS total score, and in the individual scores for pain and bowel habit compared with placebo.
Symprove addressed the range of IBS symptoms in a patient including habit (both diarrhoea & constipation). Treatment with the probiotic Symprove for 12 weeks was associated with significantly greater improvements in symptom severity (IBS-SSS) in patients with IBS as compared with placebo.
Primary endpoint was met. Improvements were observed across a range of symptoms and subtypes of IBS eg. pain, bloating, bowel habit. Most patients had mild or no symptoms at week 12 than those with placebo. Symprove was well tolerated
INDEPENDENT, single centre, double blind study involving treatment with Symprove (1 ml/kg body weight) versusplacebo for 12 weeks. Diagnosis was made according to Rome III criteria. All patients underwent extensive investigation to exclude organic disease (including intestinal permeability, faecal calprotectin, endoscopic and radiological investigation were indicated).
IBS symptom severity was measured using the IBS Symptom Severity Score (IBS-SSS). The study result showed after testing to full clinical standards, Symprove technology & its Unique Delivery System (UDS), when administered for 12 weeks was associated with significantly greater improvements in symptom severity in patients with IBS as compared with placebo.
As a result, the medical team recommend Symprove should be taken for up to 90 days to restore balance in the gut.
Buy Symprove at Simply Sunshine